EMA Authorised: Koselugo (selumetinib sulfate) — AstraZeneca AB

View source ↗

Summary

The EMA authorized Koselugo (selumetinib) for Neurofibromatosis type 1 with conditional approval and orphan medicine designation. This represents an EU-approved…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type

Drugs mentioned

• Koselugo (selumetinib)

Snippet

Status: Authorised. Therapeutic area: Neurofibromatosis 1. MAH: AstraZeneca AB. Decision date: 24/10/2025. Conditional approval. Orphan medicine